Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis

Linda L. Hushaw, Ray Sawaqed, Ghaleb Sweis, Jori Reigle, Anjali Gopal, Daniel Brandt, Nadia Sweis, James Curran, Timothy B. Niewold, Nadera J. Sweiss

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Recent advances in our understanding of the role of interleukin (IL)-6 in autoimmunity and in particular rheumatoid arthritis (RA) have brought about important changes in the way we think about autoimmune diseases. Encouraging data from several phase III clinical trials of tocilizumab, a humanized monoclonal antibody against IL-6R, have led to its approval in Europe for the treatment of moderate to severe RA. Data on clinical efficacy, patient-reported outcomes, safety, and cost-effectiveness with the use of tocilizumab in patients with RA will be summarized in this review, with particular emphasis on phase III clinical trials. Furthermore, adverse events associated with the use of tocilizumab will be reviewed. Future clinical trials will evaluate the role of tocilizumab in other autoimmune diseases. The goal of this review is to describe the current understanding of the role of IL-6 in mediating the inflammatory response in RA, as well as the role of tocilizumab in the treatment of RA and the evolving role of this agent in other autoimmune diseases.

Original languageEnglish (US)
Pages (from-to)143-152
Number of pages10
JournalTherapeutics and Clinical Risk Management
Volume6
Issue number1
StatePublished - 2010
Externally publishedYes

Fingerprint

Rheumatoid Arthritis
Disease
Autoimmune Diseases
Phase III Clinical Trials
Monoclonal antibodies
Cost effectiveness
Interleukin-6
Therapeutics
Antibodies, Monoclonal, Humanized
Interleukins
Autoimmunity
event
Cost-Benefit Analysis
costs
tocilizumab
Clinical Trials
Safety

Keywords

  • IL-6
  • Methotrexate
  • Rheumatoid arthritis
  • Tocilizumab

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research
  • Chemical Health and Safety

Cite this

Hushaw, L. L., Sawaqed, R., Sweis, G., Reigle, J., Gopal, A., Brandt, D., ... Sweiss, N. J. (2010). Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. Therapeutics and Clinical Risk Management, 6(1), 143-152.

Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. / Hushaw, Linda L.; Sawaqed, Ray; Sweis, Ghaleb; Reigle, Jori; Gopal, Anjali; Brandt, Daniel; Sweis, Nadia; Curran, James; Niewold, Timothy B.; Sweiss, Nadera J.

In: Therapeutics and Clinical Risk Management, Vol. 6, No. 1, 2010, p. 143-152.

Research output: Contribution to journalArticle

Hushaw, LL, Sawaqed, R, Sweis, G, Reigle, J, Gopal, A, Brandt, D, Sweis, N, Curran, J, Niewold, TB & Sweiss, NJ 2010, 'Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis', Therapeutics and Clinical Risk Management, vol. 6, no. 1, pp. 143-152.
Hushaw, Linda L. ; Sawaqed, Ray ; Sweis, Ghaleb ; Reigle, Jori ; Gopal, Anjali ; Brandt, Daniel ; Sweis, Nadia ; Curran, James ; Niewold, Timothy B. ; Sweiss, Nadera J. / Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. In: Therapeutics and Clinical Risk Management. 2010 ; Vol. 6, No. 1. pp. 143-152.
@article{1ca40005fb6e4bf59f2be7ae59121be8,
title = "Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis",
abstract = "Recent advances in our understanding of the role of interleukin (IL)-6 in autoimmunity and in particular rheumatoid arthritis (RA) have brought about important changes in the way we think about autoimmune diseases. Encouraging data from several phase III clinical trials of tocilizumab, a humanized monoclonal antibody against IL-6R, have led to its approval in Europe for the treatment of moderate to severe RA. Data on clinical efficacy, patient-reported outcomes, safety, and cost-effectiveness with the use of tocilizumab in patients with RA will be summarized in this review, with particular emphasis on phase III clinical trials. Furthermore, adverse events associated with the use of tocilizumab will be reviewed. Future clinical trials will evaluate the role of tocilizumab in other autoimmune diseases. The goal of this review is to describe the current understanding of the role of IL-6 in mediating the inflammatory response in RA, as well as the role of tocilizumab in the treatment of RA and the evolving role of this agent in other autoimmune diseases.",
keywords = "IL-6, Methotrexate, Rheumatoid arthritis, Tocilizumab",
author = "Hushaw, {Linda L.} and Ray Sawaqed and Ghaleb Sweis and Jori Reigle and Anjali Gopal and Daniel Brandt and Nadia Sweis and James Curran and Niewold, {Timothy B.} and Sweiss, {Nadera J.}",
year = "2010",
language = "English (US)",
volume = "6",
pages = "143--152",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis

AU - Hushaw, Linda L.

AU - Sawaqed, Ray

AU - Sweis, Ghaleb

AU - Reigle, Jori

AU - Gopal, Anjali

AU - Brandt, Daniel

AU - Sweis, Nadia

AU - Curran, James

AU - Niewold, Timothy B.

AU - Sweiss, Nadera J.

PY - 2010

Y1 - 2010

N2 - Recent advances in our understanding of the role of interleukin (IL)-6 in autoimmunity and in particular rheumatoid arthritis (RA) have brought about important changes in the way we think about autoimmune diseases. Encouraging data from several phase III clinical trials of tocilizumab, a humanized monoclonal antibody against IL-6R, have led to its approval in Europe for the treatment of moderate to severe RA. Data on clinical efficacy, patient-reported outcomes, safety, and cost-effectiveness with the use of tocilizumab in patients with RA will be summarized in this review, with particular emphasis on phase III clinical trials. Furthermore, adverse events associated with the use of tocilizumab will be reviewed. Future clinical trials will evaluate the role of tocilizumab in other autoimmune diseases. The goal of this review is to describe the current understanding of the role of IL-6 in mediating the inflammatory response in RA, as well as the role of tocilizumab in the treatment of RA and the evolving role of this agent in other autoimmune diseases.

AB - Recent advances in our understanding of the role of interleukin (IL)-6 in autoimmunity and in particular rheumatoid arthritis (RA) have brought about important changes in the way we think about autoimmune diseases. Encouraging data from several phase III clinical trials of tocilizumab, a humanized monoclonal antibody against IL-6R, have led to its approval in Europe for the treatment of moderate to severe RA. Data on clinical efficacy, patient-reported outcomes, safety, and cost-effectiveness with the use of tocilizumab in patients with RA will be summarized in this review, with particular emphasis on phase III clinical trials. Furthermore, adverse events associated with the use of tocilizumab will be reviewed. Future clinical trials will evaluate the role of tocilizumab in other autoimmune diseases. The goal of this review is to describe the current understanding of the role of IL-6 in mediating the inflammatory response in RA, as well as the role of tocilizumab in the treatment of RA and the evolving role of this agent in other autoimmune diseases.

KW - IL-6

KW - Methotrexate

KW - Rheumatoid arthritis

KW - Tocilizumab

UR - http://www.scopus.com/inward/record.url?scp=77950842174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950842174&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 143

EP - 152

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

IS - 1

ER -